Enorama Pharma (Sweden) Buy Hold or Sell Recommendation
| ERMA Stock | SEK 2.17 0.12 5.85% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding Enorama Pharma AB is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Enorama Pharma AB given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Enorama Pharma AB, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Enorama Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Enorama and provide practical buy, sell, or hold advice based on investors' constraints. Enorama Pharma AB. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Enorama |
Execute Enorama Pharma Buy or Sell Advice
The Enorama recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Enorama Pharma AB. Macroaxis does not own or have any residual interests in Enorama Pharma AB or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Enorama Pharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Enorama Pharma Trading Alerts and Improvement Suggestions
| Enorama Pharma AB generated a negative expected return over the last 90 days | |
| Enorama Pharma AB has high historical volatility and very poor performance | |
| Enorama Pharma AB has accumulated 1.7 M in total debt with debt to equity ratio (D/E) of 6.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Enorama Pharma AB has a current ratio of 0.51, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Enorama Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Enorama Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Enorama Pharma AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Enorama to invest in growth at high rates of return. When we think about Enorama Pharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 11.04 M. Net Loss for the year was (27.74 M) with profit before overhead, payroll, taxes, and interest of 3.9 M. | |
| Enorama Pharma AB has accumulated about 2.01 M in cash with (30.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38. | |
| Roughly 78.0% of Enorama Pharma shares are held by company insiders |
Enorama Pharma Returns Distribution Density
The distribution of Enorama Pharma's historical returns is an attempt to chart the uncertainty of Enorama Pharma's future price movements. The chart of the probability distribution of Enorama Pharma daily returns describes the distribution of returns around its average expected value. We use Enorama Pharma AB price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Enorama Pharma returns is essential to provide solid investment advice for Enorama Pharma.
| Mean Return | -0.67 | Value At Risk | -11.59 | Potential Upside | 7.72 | Standard Deviation | 5.71 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Enorama Pharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Enorama Pharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Enorama Pharma or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Enorama Pharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Enorama stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.67 | |
β | Beta against Dow Jones | 1.04 | |
σ | Overall volatility | 5.76 | |
Ir | Information ratio | -0.12 |
Enorama Pharma Volatility Alert
Enorama Pharma AB exhibits very low volatility with skewness of -0.12 and kurtosis of -0.76. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Enorama Pharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Enorama Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Enorama Pharma Fundamentals Vs Peers
Comparing Enorama Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Enorama Pharma's direct or indirect competition across all of the common fundamentals between Enorama Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Enorama Pharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Enorama Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Enorama Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Enorama Pharma to competition |
| Fundamentals | Enorama Pharma | Peer Average |
| Return On Equity | -32.88 | -0.31 |
| Return On Asset | -0.53 | -0.14 |
| Operating Margin | (3.11) % | (5.51) % |
| Current Valuation | 42.1 M | 16.62 B |
| Shares Outstanding | 10.69 M | 571.82 M |
| Shares Owned By Insiders | 78.21 % | 10.09 % |
| Shares Owned By Institutions | 1.31 % | 39.21 % |
| Price To Book | 7.67 X | 9.51 X |
| Price To Sales | 3.82 X | 11.42 X |
| Revenue | 11.04 M | 9.43 B |
| Gross Profit | 3.9 M | 27.38 B |
| EBITDA | (25.56 M) | 3.9 B |
| Net Income | (27.74 M) | 570.98 M |
| Cash And Equivalents | 2.01 M | 2.7 B |
| Cash Per Share | 0.38 X | 5.01 X |
| Total Debt | 1.7 M | 5.32 B |
| Debt To Equity | 6.00 % | 48.70 % |
| Current Ratio | 0.52 X | 2.16 X |
| Book Value Per Share | (1.22) X | 1.93 K |
| Cash Flow From Operations | (30.16 M) | 971.22 M |
| Earnings Per Share | (4.92) X | 3.12 X |
| Number Of Employees | 10 | 18.84 K |
| Beta | 1.65 | -0.15 |
| Market Capitalization | 89.44 M | 19.03 B |
| Total Asset | 50.93 M | 29.47 B |
| Z Score | 31.2 | 8.72 |
| Net Asset | 50.93 M |
Enorama Pharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Enorama . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Enorama Pharma Buy or Sell Advice
When is the right time to buy or sell Enorama Pharma AB? Buying financial instruments such as Enorama Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Enorama Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Blend Funds Thematic Idea Now
Small Blend Funds
Fund or Etfs that invest in stocks of small to mid-sized entities that have characteristics of both growth and value companies. The Small Blend Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Blend Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Enorama Stock Analysis
When running Enorama Pharma's price analysis, check to measure Enorama Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enorama Pharma is operating at the current time. Most of Enorama Pharma's value examination focuses on studying past and present price action to predict the probability of Enorama Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enorama Pharma's price. Additionally, you may evaluate how the addition of Enorama Pharma to your portfolios can decrease your overall portfolio volatility.